DCAT Value Chain Insights

Drug Development and the Impact of COVID-19

With a cost of $2.6 billion to bring a new drug to market, a slowing of drug-development activities can have a significant cost to both pharmaceutical companies and CDMOs/CMOs. To address impacts of...

Indian Government Looks To Increase Domestic API Mfg

In response to the novel coronavirus and India's reliance on active pharmaceutical ingredient (API) production outside of the country, the Indian government has put forth a $1.3-billion multi-year...

Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

Information
March 9, 2020
Sponsored by Cambrex

Stephan Haitz, President, CDMO Sales & Marketing discusses small molecule trends and how the CDMO industry is constantly evolving to meet the demands and needs of the growing clinical pipeline.

Read More
A Cambrex Webinar- De-Risking the Solid Form Landscape of an API

Information
February 24, 2020
Sponsored by Cambrex

Dr. David Pearson, Chief Scientific Officer of Cambrex Edinburgh, discusses how a full understanding of the crystalline landscape of an active pharmaceutical ingredient (API) molecule can predict...

Read More
Future focus: Our 2020 vision

Information
February 11, 2020
Sponsored by Cambrex

Cambrex eBook: The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021, driven by positive industry trends — many of which our experts commented on in Part 1...

Read More